Relapsed Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemia responds well to a combination of modified hyper‐CVAD, blinatumomab and tyrosine kinase inhibitor

Abstract Introduction Adults with relapsed or refractory Philadelphia chromosome‐positive B‐cell precursor acute lymphoblastic leukaemia (R/R Ph+ BCP‐ALL) have a dismal outcome. Blinatumomab as a single agent has shown activity in R/R Ph‐ BCP‐ALL, and second or third‐generation tyrosine kinase inhib...

Full description

Bibliographic Details

Published in:	eJHaem
Main Authors:	Gaétan Basile, Jean Galtier, Titouan Cazaubiel, Edouard Forcade, Emilie Klein, Audrey Bidet, Carmen Botella‐Garcia, Clémence Mediavilla, Laurence Clement, Pierre‐Yves Dumas, Arnaud Pigneux, Thibaut Leguay
Format:	Article
Language:	English
Published:	Wiley 2025-02-01
Subjects:	acute leukaemia ALL immunotherapy tyrosine kinases
Online Access:	https://doi.org/10.1002/jha2.1064